American Academy of Dermatology

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO RELIEVE ITCHY PSORIASIS

Retrieved on: 
Thursday, March 23, 2023
Infection, Hair, American Academy of Dermatology, Diabetes, Eastern Virginia Medical School, Sleep, Cardiovascular disease, Nail, Psoriasis, Quality of life, American Academy, FAAD, Scalp, Patient, AAD, Risk, Water, Bath, Joint, Diagnosis, Itch, Health, Menthol, Skin, Medical device, Cosmetics

ROSEMONT, Ill., March 23, 2023 /PRNewswire/ -- Skin issues can have a serious impact on your health and well-being. For the 7.5 million Americans1 living with psoriasis, itch can be the most bothersome part of their condition because it can make it difficult to sleep and hard to concentrate, as well as affect other aspects of their quality of life. To help relieve your psoriasis itch, a board-certified dermatologist from the American Academy of Dermatology (AAD) is providing four important tips to consider.

Key Points: 
  • To help relieve your psoriasis itch, a board-certified dermatologist from the American Academy of Dermatology (AAD) is providing four important tips to consider.
  • "That's why it's so important to know how to relieve your itch so this doesn't happen."
  • To ease itch caused by your psoriasis, Dr. Pariser and the AAD recommend these tips:
    Limit time in water to avoid drying your skin.
  • These tips are demonstrated in " How to Relieve Itchy Psoriasis ," a video posted to the AAD website and YouTube channel .

DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, March 22, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, American Academy of Dermatology, Hypopigmentation, Therapy, SKS, Cryosurgery, Neoplasm, Food, Edema, Clinical trial, Scar, American Academy, Itch, Pain, Erythema, Patient, AKT, AAD, Risk, BID, Apoptosis, Hyperpigmentation, PLA, Entrepreneurship, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Skin, Safety, Casting, Pharmaceutical industry, Wood-plastic composite

SM-020 is a selective and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK) lesions.

Key Points: 
  • SM-020 is a selective and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK) lesions.
  • SKs are currently treated with ablative surgical procedures and there is currently no available topical therapy for these tumors.
  • DermBiont’s Phase 2 proof-of-concept, adaptive open-label trial tested SM-020 gel 0.1% and 1.0%, enrolling 35 subjects with 4 SK target lesions across seven treatment cohorts.
  • "We are pleased to have presented positive results from our Phase 2 adaptive, open-label trial with SM-020 at the prominent AAD annual meeting.

The Inner Circle Acknowledges, Dr. Jason Chouake as a Top Pinnacle Healthcare Professional for his contributions to the field of Dermatology

Retrieved on: 
Tuesday, March 21, 2023
American Academy of Dermatology, Travel, Dermatitis, Skin cancer, American Academy, Moles, Multimedia, Inner circle, Psoriasis, Yeshiva University, MD, Family, Veterinary medicine, Dermatology

CLIFFSIDE PARK, N.J., March 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Jason Chouake is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Dermatology.

Key Points: 
  • CLIFFSIDE PARK, N.J., March 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Jason Chouake is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Dermatology.
  • He then earned his MD from Albert Einstein School of Medicine, Monetfiore, where he also completed his residency in Dermatology.
  • Dr. Chouake received the Distinction in Dermatological Research Award during his residency at Albert Einstein School of Medicine.
  • Dr. Chouake is a Fellow of the American Academy of Dermatology and a member of the International Peeling Society.

Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting

Retrieved on: 
Monday, March 20, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, University, TAK, American Academy, Psoriasis, Patient, AAD, TYK2, American Academy of Dermatology, PASI, MPH, Therapy, Dean (education), Pharmaceutical industry, Takeda, Dermatology

Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans.

Key Points: 
  • Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans.
  • The results were presented as part of the Late-Breaking Research session by April Armstrong, M.D., MPH, clinical investigator in the Phase 2b study and Associate Dean and Professor of Dermatology at the University of Southern California.
  • A PGA score of 1 indicates almost clear skin and 0 indicates totally clear skin.
  • We have advanced our leading-edge technologies and grown our expertise in small molecule drug development to deliver breakthrough medicines, by design, for the benefit of patients.”

MatriSys Bioscience Co-Founder Richard Gallo, MD, PhD Honored by AAD and AAAAI

Retrieved on: 
Monday, March 20, 2023
Eugene, Piper LBP, American Academy of Dermatology, Skin, BOCA, Atopic dermatitis, American Academy, Research, AAD, AAAAI, Innovation, Health, New Orleans, Pharmaceutical industry, Medical device, Bedside

BOCA RATON, Fla., March 20, 2023 /PRNewswire/ -- MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic dermatologic indications, today announced that its scientific co-founder, Dr. Richard Gallo, received the Eugene J Van Scott award for Innovative Therapy of the Skin from the American Academy of Dermatology (AAD).

Key Points: 
  • BOCA RATON, Fla., March 20, 2023 /PRNewswire/ -- MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic dermatologic indications, today announced that its scientific co-founder, Dr. Richard Gallo, received the Eugene J Van Scott award for Innovative Therapy of the Skin from the American Academy of Dermatology (AAD).
  • This award was created in 2007 to recognize innovation in the treatment of skin diseases and conditions.
  • Dr. Gallo will be presenting the Philip Frost Leadership lecture during the AAD conference plenary session in New Orleans LA on March 19.
  • The application of Dr. Gallo's research into the microbiome of the skin provides new opportunities to advance patient care in atopic dermatitis and other chronic conditions.

LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting

Retrieved on: 
Saturday, March 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Conditional sentence, University, Leo Pharma, BV, Aes, COVID-19, American Academy, Atopic dermatitis, Development, Dermatology, MD, Patient, AAD, LEO, American Academy of Dermatology, Cytokine, Upper respiratory tract infection, Safety, Pharmaceutical industry, EASI

LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
  • Results were shared as one of two LEO Pharma late breaker oral presentations at the 2023 American Academy of Dermatology (AAD) Annual Meeting.1 LEO 138559 is an investigational agent and its efficacy and safety are subject to further larger trials.
  • LEO Pharma and argenx BV jointly developed LEO 138559 under an exclusive option and research agreement.
  • LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Retrieved on: 
Saturday, March 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, JAK1, American Academy, LSM, Patient, AAD, Week, Safety, American Academy of Dermatology, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
  • Results from the study demonstrate that treatment with oral povorcitinib was associated with substantial total body repigmentation in patients with extensive nonsegmental vitiligo, as measured by total Vitiligo Area Scoring Index (T-VASI) scores.
  • “Vitiligo is a chronic, immune-mediated disease which, until recently, had limited treatment options available to patients.
  • “As vitiligo can impact patients in different ways, I am encouraged by the continued focus on expanding medical treatment options, and I believe these data highlight the potential of this investigational oral treatment for patients with extensive nonsegmental vitiligo.”

LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023

Retrieved on: 
Saturday, March 18, 2023
Managed Care, Pharmaceutical, Health, Clinical Trials, Janus, American Academy of Dermatology, American Academy, JAK, IGA, Leo Pharma, Patient, AAD, CHE, DELTA, Week, Safety, LEO, Pharmaceutical industry, Silviculture

The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.

Key Points: 
  • The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.
  • A significantly greater proportion of delgocitinib-treated patients, compared to cream vehicle, achieved this IGA-CHE improvement (19.7% vs. 9.9%; p=0.006).
  • A significantly greater proportion of delgocitinib-treated patients achieved a ≥75% improvement in Hand Eczema Severity Index (HECSI-75) compared to cream vehicle (49.2% vs. 23.5%; p
  • We are incredibly excited to share the positive results of this trial, which demonstrates the potential that delgocitinib cream has as a first-in-class innovative topical treatment.”

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

Retrieved on: 
Saturday, March 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Inflammation, Week, The New England Journal of Medicine, Autoimmunity, American Academy, Depigmentation, Patient, AAD, BID, American Academy of Dermatology, Vitiligo, LTE, Skin, Safety, Pharmaceutical industry

The 104-week long-term extension (LTE) data build on the positive 52-week TRuE-V1 and TRuE-V2 results previously announced and published in The New England Journal of Medicine.

Key Points: 
  • The 104-week long-term extension (LTE) data build on the positive 52-week TRuE-V1 and TRuE-V2 results previously announced and published in The New England Journal of Medicine.
  • “The results presented today at AAD are significant because they provide important long-term efficacy and safety data for nonsegmental vitiligo patients treated with Opzelura,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • Approximately 29% of patients randomized to the withdrawal arm (i.e., applying vehicle cream) relapsed (
  • “Vitiligo is a chronic condition and these results demonstrate the long-term potential of this medical treatment for people with vitiligo who are interested in repigmentation.”

AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis

Retrieved on: 
Saturday, March 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Pharmacokinetics, American Academy, Associate, Prurigo, Skin, Patient, AAD, Itch, American Academy of Dermatology, Prurigo nodularis, Nemolizumab, III, Safety, Johns Hopkins School of Medicine, Pharmaceutical industry, Dermatology

Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.

Key Points: 
  • Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.
  • The phase III OLYMPIA 2 trial met all primary endpoints, showing nemolizumab monotherapy significantly improved pruritus (itch) and skin lesions compared with placebo in adult patients with moderate to severe prurigo nodularis.
  • “We are so pleased that we’re able to bring so much powerful new data to this year’s AAD congress.
  • Its continued commitment to delivering science and innovation across a highly differentiated portfolio is reflected in its extensive presence at AAD.